Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-2 vs Hexarelin
An educational, source-based comparison of GHRP-2 and Hexarelin — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide that activates the ghrelin/GHS-R1a receptor, stimulating endogenous GH release. Compared to Ipamorelin, GHRP-2 produces a stronger GH pulse but also modestly elevates cortisol, prolactin, and appetite.
- GH release in adult GH deficiency
- Appetite stimulation in cachexia models
- Diagnostic GH stimulation testing
- • Not FDA-approved.
- • Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- • Prohibited by WADA.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-2 | GHRP-2 stimulates GH release in healthy and GH-deficient adults | Journal of Clinical Endocrinology & Metabolism | 1997 | Established robust GH response after subcutaneous administration. |
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
Side-effect & safety grid
- Not FDA-approved.
- Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- Prohibited by WADA.
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-2 vs Hexarelin — Key differences
- Class: GHRP-2 is classified as Growth Hormone Axis, while Hexarelin is Growth Hormone Axis · Cardiac.
- Primary research focus: GHRP-2 — gh release in adult gh deficiency; Hexarelin — gh release.
- Tag: Growth hormone vs Growth hormone.